March 22nd 2024
Here is a review of the effectiveness of fidaxomicin vs vancomycin for CDI treatment in populations with immunocompromised conditions.
Ferring’s Microbiome Health Index Measures Gut Microbiota After Antibiotics
January 7th 2022Ferring’s Microbiome Health Index is a diagnostic tool that may help distinguish a healthy gut microbiome from post-antibiotic dysbiosis, and could potentially identify debilitating illnesses such as C difficile infection
Read More
Taking Care of Each Other: The Peggy Lillis Foundation for C Diff Education and Advocacy
December 14th 2021Christian Lillis, co-founder and executive director of the Peggy Lillis Foundation (PLF) for C diff Education & Advocacy, says that taking care of each other is often the best way to stop the spread of infectious diseases.
Watch
Who Is at Risk for Developing Clostridioides Difficile Infection?
An overview of the risk factors that contribute to the development of Clostridioides difficile infection in various health care settings.
Watch
Identifying CDI: Presentation, Prevalence, and Spectrum of Disease
Comprehensive discussion on the identification of Clostridioides difficile infection, the spectrum of disease, and overall epidemiology.
Watch
Understanding How Disruption of the Gut Microbiome Leads to CDI
The panel reflects on how disruption of the gut microbiome leads to the proliferation of Clostridioides difficile.
Watch
C Difficile Infection: What Causes Disruption of the Gut Microbiome?
Shared insight on how disruption of the gut microbiome may occur based on antibiotic exposure, environmental factors, and diet.
Watch
C Difficile Infection: The Importance of the Gut Microbiome
Opening their discussion on Clostridioides difficile, experts provide an overview on the gut microbiome and colonization resistance.
Watch
Investigational Therapies, Modalities May Change Recurrent C Difficile Treatment Trajectory
November 11th 2021During the C Diff Foundation's Annual conference, providers and stakeholders offered insights on the latest investigational therapies and modalities as they advance through clinical trials.
Watch